#United States #Dallas #Bio-Techne #ProPak cytokines #G-Rex bioreactor

Bio-Techne at Phacilitate's Advanced Therapies Week 2025

Bio-Techne Corporation is set to make waves at the upcoming Phacilitate Advanced Therapies Week, scheduled for January 20-23, 2025, at the Kay Bailey Hutchison Convention Center in Dallas, Texas. This event is a key gathering for leaders in cell and gene therapy, and Bio-Techne’s participation demonstrates their commitment to innovating in this crucial field of medical science.

Innovative Products on Display

At this highly anticipated event, Bio-Techne will highlight its new ProPak™ GMP cytokines, pivotal for enhancing the efficiency of cell and gene therapy manufacturing. Attendees can visit booth 517 to explore the full range of Bio-Techne's cutting-edge solutions designed to streamline and boost the reproducibility and scalability of therapeutic workflows.

Featured Innovations: ProPak™ Cytokines and More

Among the featured products is the ProPak liquid GMP cytokines. These cytokines are engineered to work seamlessly with Wilson Wolf's G-Rex® bioreactor system, provided through their strategic partner ScaleReady. The integration of ProPak cytokines and G-Rex technology allows for a closed process, optimizing cytokine delivery for T cell manufacturing while minimizing risks.

In addition, Bio-Techne will showcase the Ella™ automated ELISA platform alongside its Simple Plex™ assays, which are designed specifically for quality control release testing. The booth promises an extensive display of Bio-Techne's protein analytical instruments, crucial for in-process and final product characterization in cell and gene therapies.

Insight from Experts

Attendees will also have the opportunity to hear from Dr. David Hermanson, Bio-Techne’s Principal Scientist for Cell & Gene Therapy Research and Development. Dr. Hermanson's breakout session, scheduled for January 21 at 12:15 PM, will delve into closed system manufacturing. Key topics will include strategies for maintaining flexibility and scalability through all phases of cell therapy development, while also tackling critical regulatory and quality control considerations.

Dr. Hermanson will further highlight the practical applications of integrating ProPak cytokines into T cell manufacturing processes during a live demonstration in the Innovation Zone on January 22 at 10:00 AM. This session promises to shed light on the advantages offered by closed system solutions, empowering professionals in the field with valuable knowledge.

Commitment to Advancing Therapy Manufacturing

With its focus on lifesaving cell therapies, Bio-Techne is steadfast in its mission to enhance manufacturing efficacy for CAR-T and TCR-T cell products. President Will Geist of Bio-Techne's Protein Sciences Segment articulated the company's vision: “ProPak GMP Cytokines deliver the precise quantities necessary for the streamlined expansion of cell therapies, ensuring exceptional cell characteristics.”

As Bio-Techne prepares for its presence at Phacilitate's Advanced Therapies Week, anticipation builds around their showcase of innovative solutions and expert insights. The conference serves as an essential platform for industry leaders, which aims at driving forward the next generation of therapeutic solutions that can change lives.

For more information on Bio-Techne and its product offerings, or to follow their ongoing developments, visit their official website at Bio-Techne or connect with them through social media channels.

As the life sciences industry continues to evolve, Bio-Techne remains at the forefront, ready to support researchers and clinicians in the quest for groundbreaking therapies.